O Shaughnessy Asset Management LLC Acquires Shares of 31,909 Apyx Medical Corp (NASDAQ:APYX)

O Shaughnessy Asset Management LLC acquired a new stake in Apyx Medical Corp (NASDAQ:APYX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 31,909 shares of the company’s stock, valued at approximately $200,000. O Shaughnessy Asset Management LLC owned about 0.09% of Apyx Medical as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Menta Capital LLC bought a new position in shares of Apyx Medical in the first quarter valued at $65,000. Sheaff Brock Investment Advisors LLC bought a new position in shares of Apyx Medical in the first quarter valued at $66,000. Steward Partners Investment Advisory LLC bought a new position in shares of Apyx Medical in the first quarter valued at $68,000. Keybank National Association OH bought a new position in shares of Apyx Medical in the first quarter valued at $82,000. Finally, Nkcfo LLC acquired a new stake in Apyx Medical during the 1st quarter valued at $96,000. 45.39% of the stock is owned by institutional investors.

Shares of NASDAQ APYX traded up $0.23 during mid-day trading on Monday, hitting $6.95. The company had a trading volume of 297,595 shares, compared to its average volume of 315,144. Apyx Medical Corp has a 12 month low of $3.55 and a 12 month high of $8.89. The company has a market cap of $227.93 million, a price-to-earnings ratio of -23.97 and a beta of 0.11. The firm’s 50-day moving average price is $6.12.

Apyx Medical (NASDAQ:APYX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. Apyx Medical had a net margin of 224.06% and a negative return on equity of 12.25%. The firm had revenue of $5.82 million during the quarter. As a group, equities analysts forecast that Apyx Medical Corp will post -0.69 EPS for the current fiscal year.

APYX has been the topic of several recent analyst reports. ValuEngine downgraded shares of Apyx Medical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, April 3rd. Zacks Investment Research downgraded shares of Apyx Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 18th. TheStreet cut shares of Apyx Medical from a “c-” rating to a “d” rating in a report on Monday, May 20th. Piper Jaffray Companies decreased their price objective on shares of Apyx Medical to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 8th. Finally, JMP Securities decreased their price objective on shares of Apyx Medical from $12.00 to $8.00 and set a “market outperform” rating for the company in a report on Tuesday, April 2nd. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Apyx Medical currently has a consensus rating of “Buy” and an average price target of $8.00.

About Apyx Medical

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Featured Article: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for Apyx Medical (NASDAQ:APYX)

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.